IL283502A - Alactestrant in combination with abmicislib in women with breast cancer - Google Patents

Alactestrant in combination with abmicislib in women with breast cancer

Info

Publication number
IL283502A
IL283502A IL283502A IL28350221A IL283502A IL 283502 A IL283502 A IL 283502A IL 283502 A IL283502 A IL 283502A IL 28350221 A IL28350221 A IL 28350221A IL 283502 A IL283502 A IL 283502A
Authority
IL
Israel
Prior art keywords
elacestrant
abemaciclib
women
combination
breast cancer
Prior art date
Application number
IL283502A
Other languages
English (en)
Hebrew (he)
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of IL283502A publication Critical patent/IL283502A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL283502A 2018-11-30 2021-05-27 Alactestrant in combination with abmicislib in women with breast cancer IL283502A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773960P 2018-11-30 2018-11-30
PCT/US2019/063239 WO2020112765A1 (en) 2018-11-30 2019-11-26 Elacestrant in combination with abemaciclib in women with breast cancer

Publications (1)

Publication Number Publication Date
IL283502A true IL283502A (en) 2021-07-29

Family

ID=68966023

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283502A IL283502A (en) 2018-11-30 2021-05-27 Alactestrant in combination with abmicislib in women with breast cancer

Country Status (18)

Country Link
US (3) US20220117963A1 (enExample)
EP (1) EP3886826A1 (enExample)
JP (2) JP2022509262A (enExample)
KR (1) KR20210097170A (enExample)
CN (1) CN113164415A (enExample)
AU (1) AU2019388900B2 (enExample)
BR (1) BR112021010169A2 (enExample)
CA (1) CA3120368A1 (enExample)
EA (1) EA202191165A1 (enExample)
IL (1) IL283502A (enExample)
JO (1) JOP20210125A1 (enExample)
MA (1) MA54293A (enExample)
MX (1) MX2021005876A (enExample)
MY (1) MY209833A (enExample)
PH (1) PH12021551235A1 (enExample)
SG (1) SG11202105455RA (enExample)
UA (1) UA129403C2 (enExample)
WO (1) WO2020112765A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
WO2022106711A1 (en) * 2020-11-23 2022-05-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP7846700B2 (ja) * 2021-02-16 2026-04-15 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
CN114146182A (zh) * 2021-11-12 2022-03-08 深圳大学 Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384605B (es) * 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
WO2017160990A1 (en) * 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
WO2018017410A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer

Also Published As

Publication number Publication date
US20250268899A1 (en) 2025-08-28
JP2022509262A (ja) 2022-01-20
CA3120368A1 (en) 2020-06-04
JOP20210125A1 (ar) 2019-11-26
KR20210097170A (ko) 2021-08-06
MA54293A (fr) 2021-10-06
WO2020112765A1 (en) 2020-06-04
MY209833A (en) 2025-08-07
BR112021010169A2 (pt) 2021-08-17
SG11202105455RA (en) 2021-06-29
AU2019388900B2 (en) 2025-09-04
MX2021005876A (es) 2021-07-16
US20260014153A1 (en) 2026-01-15
UA129403C2 (uk) 2025-04-16
JP2025094216A (ja) 2025-06-24
CN113164415A (zh) 2021-07-23
EA202191165A1 (ru) 2021-09-21
US20220117963A1 (en) 2022-04-21
AU2019388900A1 (en) 2021-06-10
EP3886826A1 (en) 2021-10-06
PH12021551235A1 (en) 2021-12-13

Similar Documents

Publication Publication Date Title
SG11202105455RA (en) Elacestrant in combination with abemaciclib in women with breast cancer
SG11202104356VA (en) Bt1718 for use in treating cancer
ZA201801036B (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202005950XA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SMT202500362T1 (it) Anticorpi anti-fgfr2 in combinazione con agenti chemioterapici nel trattamento del cancro
SI3474841T1 (sl) Postopki zdravljenja raka dojke AR+
EP3134115A4 (en) Methods and compositions for treating metastatic breast cancer and other cancers in the brain
SG10202008070XA (en) Uterine cancer treatments
PL3756493T3 (pl) Odzież i biustonosz
ZA202102740B (en) Anti-liv1 immune cell cancer therapy
ZA202102745B (en) Anti-ptk7 immune cell cancer therapy
ZA202000851B (en) Antibodies useful in cancer diagnosis
EP3353554A4 (en) BIOMARKERS FOR THE DETECTION OF BREAST CANCER IN WOMEN WITH DENSE BREASTS
SG11202008193XA (en) Brassiere
PL3253208T3 (pl) Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
GB2579328B (en) Breast cancer detection
GB2577116B (en) Brassiere
IL259241A (en) Combination of tumor characteristics with breast cancer index
GB201800733D0 (en) Cancer
SG11202007005UA (en) Use of crassocephalum rabens extract in the treatment of breast cancer
IL262143A (en) Improvements in cancer treatment
GB201814487D0 (en) Cancer
SG11202105276TA (en) Oligo-benzamide analogs and their use in cancer treatment
GB201614955D0 (en) Brassiere with breast seperator
HK40062951A (en) Elacestrant in combination with abemaciclib in women with breast cancer